The promise of antisense oligonucleotides in precision medicine

Antisense oligonucleotides (ASOs) are gaining popularity among drug developers due to their specificity and versatility in treating various diseases. Despite challenges including insufficient biological activity and off-target toxic effects, recent advancements have made ASOs more stable and easier to administer. ASOs have potential in treating central nervous system disorders, ophthalmic diseases, and oncology, among others. However, more research is required to unlock their full potential across all disease areas. The global ASOs market is expected to reach around $5,519 million by 2033.